Bain Capital

Surf internet offers fiber-optic internet access. They provide fiber optic internet, wireless internet, whole-home wifi, and streaming TV services. They offer high-speed, dependable internet service. In the communities where they live, work, and serve, they provide customer service.

Nimbus Apollo is a program under Nimbus Therapeutics that focuses on the development of innovative treatments for serious diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The program's lead candidate, NDI-010976, is an allosteric inhibitor of Acetyl-CoA Carboxylase (ACC), which has received Fast Track designation from the U.S. Food and Drug Administration. Nimbus Apollo is engaged in advancing this candidate through various stages of clinical development, with Phase 1 data expected to be presented at notable medical conferences. Nimbus Therapeutics, founded in 2009 and based in Cambridge, Massachusetts, leverages computational technology to design selective and potent small molecule therapeutics aimed at addressing metabolic diseases, cancer, and immune-inflammatory disorders. The company has established strategic partnerships to enhance its research and development efforts.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Cuisine Solutions, Inc. is a provider of sous-vide products. The Company's range of sous-vide products include beef, lamb, pork, veal, pasta and sides, poultry, sauces, seafood and vegetarian.

Bubbles is a contextual collaboration tool that enables users to communicate asynchronously by tagging content directly on their screens. The platform facilitates discussions in-context through screen, video, and audio messages, allowing team members to capture, comment, and share information without the need for account creation or installation. Bubbles promotes organic growth and viral engagement rather than relying on paid advertising. It is actively engaged on various social media platforms, including Medium, Twitter, and Product Hunt, to enhance its visibility and user interaction.

IIFL Holdings Limited, previously known as India Infoline Limited, serves as the apex holding company for the IIFL Group, a prominent financial services entity in India. The company offers a diverse range of financial products and services, including credit and finance, wealth management, asset management, financial product distribution, capital market advisory, and investment banking. IIFL primarily targets retail customers, boasting a client base of over 2 million, which includes many first-time investors in mutual funds, insurance, and consumer credit. This extensive reach is supported by more than 2,700 business locations and innovative marketing strategies, such as seminar sales and mobile vans for outreach in smaller regions. With a significant focus on non-banking financial services, IIFL's lending and NBFC operations constituted a substantial portion of its income. The company is recognized as a leader in the distribution of life insurance and mutual funds among non-bank entities, while maintaining a strong presence in both retail and institutional equity broking.

FreeWill is an online service that provides legal forms and legal information. FreeWill is an award-winning social venture founded by graduate students at Stanford University in 2016, with the help and support of many of the world’s leading experts in law, design, and philanthropy. The company is making estate planning warm, accessible, and totally free – so that you can more easily care for the people and causes you love.

Overview.ai provides real time fault detection that uses cameras and AI to monitor manufacturing robots, shutting them down if something goes wrong. Its smart camera automatically learns normal machine routines to detect any deviations, crashes or anomalies. Its system catches misalignments, breakage, and out-of-sequence behavior before significant damage occurs to product or machine.

Swoogo is the #1 event marketing software for planners who like to get sh!t done. Whether your events are live, hybrid, or virtual, we gotchu— with the world’s smartest registration, easiest site builder, and best customer service. Pepper in unlimited events, unlimited registrations, and unlimited free integrations and you’ve got yourself a turkey. Let’s get sh!t done together.

Zero Hash, founded in 2017 and based in Chicago, Illinois, provides a post-trade settlement utility designed to unify a fragmented market of various execution platforms. The company supports a diverse array of fiat and digital assets, allowing for the creation of any product pair. Additionally, Zero Hash incorporates on-chain settlement for digital assets, enabling independent verification of ownership through blockchain technology. This combination of features aims to enhance the efficiency and transparency of digital asset transactions in the financial ecosystem.

Origem is based in Brazil.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Hometap Equity Partners, LLC provides near-immediate access to funds to homeowners for the things they need and want without having to incur further debt through a home equity loan or second mortgage. The company provides home equity investments with no set credit score, no interest rates, and no monthly payments to change the face of homeownership and provide financial stability to homeowners. It also develops a data-driven home equity investment platform to extend its initiatives to educate homeowners. The company was founded in 2017 and is based in Boston, Massachusetts.

PeopleFund is Korea’s leading tech-based financial platform that is opening doors to financial freedom through affordable loans and attractive alternative investment products. It is the fastest growing marketplace lender in Korea and uniquely positioned as the first and only Korean marketplace lending platform to fully integrate with a top-tier commercial bank to process personal and business loans that are government approved. PeopleFund is also the first fintech platform to offer investment products directly on KakaoTalk, Korea’s most popular messaging app, which has allowed the company to grow and scale up its business. PeopleFund was founded in 2015 and is headquartered in Seoul, Korea.

RentoMojo is an online furniture rental platform that was incorporated in November 2014.It currently operates in Bangalore, Pune, Mumbai, Hyderabad, Chennai, Delhi, Gurgaon and Noida. RentoMojo was founded by Geetansh Bamania, an ex-IITM, in November 2014 in India. Like many other young working professionals, he was living in rented apartments, working long hours and found it inconvenient to equip the house with furniture when he moved. RentoMojo was developed to provide an alternative to buying and selling furniture in rental properties.

Linc'well Inc. is a Tokyo-based company founded in 2018 that develops a software platform aimed at improving operations within the healthcare sector. The company offers a software as a service (SaaS) solution that facilitates various functions such as web inquiries, call management, payment processing, and electronic medical records management. In addition to these core services, Linc'well provides operational and management support through its brand CLINIC FORE, as well as online services that include medical supplement subscriptions. By serving healthcare institutions and clinics, Linc'well aims to enhance the patient experience and increase the efficiency of clinic management.

HiMama provides a quick and easy way for childcare programs and parents to record and share children's activities, everything from silly and fun moments to learning and developmental milestones. The solution for childcare and early learning programs is based on extensive research and interviews with early childhood educators and enables quick and intuitive recording of observations in the early childhood setting, as well as instant sharing with parents through real-time emails and updates through mobile apps. In addition to staying informed on their children's activities while in childcare programs, parents can also log their children’s activities so they’ll never forget their favorite stories and can always relive through photos and videos in their child's online journal.

When I Work is an employee scheduling and communication app using the web, mobile apps, text messaging, social media, and email. The program provides a powerful tool for employers to communicate with employees and ensure schedules are properly communicated. It is a developer of a human resource management platform designed to create transformative, simple products that help hourly employees and managers work better together. Founded in 2010, it improves operational efficiency, drive employee accountability via self-service, and control labor costs.

Gluware, Inc. specializes in developing automation and orchestration software for multi-vendor and multi-domain networks. The company's flagship product, Gluware Control, features a data-model driven platform that employs an intent-based, network-aware orchestration engine. This platform includes tools for configuration management, monitoring, and IT system workflow management, with capabilities such as configuration drift auditing, software upgrade management, and WAN traffic routing. Gluware's solutions facilitate the management of both physical and virtual network functions, enhancing security and compliance across network devices. Founded in 2007 and based in Sacramento, California, Gluware has established itself as a leader in network lifecycle management, helping enterprises and managed service providers implement complex network and security features while minimizing deployment and support costs. The company was previously known as Glue Networks, Inc. before rebranding in 2017.

Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.

Cotopaxi is a direct-to-consumer, outdoor gear, and apparel company with a social-focused mission of eradicating extreme poverty. Every piece of gear is tied to a humanitarian cause in the world’s poorest countries. Every pack provides between one and three weeks of education to a child, the sale of a water bottle provides six months of clean water and all apparel is tied to health related projects. Cotopaxi's aim is to help the world's poorest of the poor and to provide transparency by showing the exact impact of donations. It was founded in 2014 and headquartered in Salt Lake City, Utah.

The Berlin Brands Group - part of Chal-Tec GmbH - is a globally active vertical commerce company with brands from Home & Living, Consumer Electronics, Sound & Light and Sports, united under one roof. Since its foundation in 2005 by Peter Chaljawski it is one of Germany's top-selling digital companies. The Berlin Brands Group (BBG) encompasses its portfolio’s entire value chain: from product development, conception and design to production, marketing and customer service. From its headquarters in Berlin, the vertical commerce company manages the brand development and multi-channel distribution of more than 3,700 products for consumers in 28 countries worldwide. More than 900 employees currently work at the six locations in Berlin (headquarters), Kamp-Lintfort (logistics centre), Bratislava, Istanbul, Hong Kong and San Francisco. OUR BRANDS Klarstein - https://www.klarstein.de/ Capital Sports - https://www.capitalsports.de/ auna - https://www.auna.de/ blumfeldt - https://www.blumfeldt.de/ Numan - https://www.numanaudio.com/

Imperative Care, Inc. is a medical technology company dedicated to enhancing acute stroke treatment. Founded in 2015 and based in Campbell, California, the company develops innovative solutions aimed at addressing critical needs in stroke care. Its primary offerings include the Large Distal Platform, a large diameter catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic strokes. Additionally, the ZOOM Aspiration System works in conjunction with the Large Distal Platform, providing a comprehensive solution for clot removal across various occlusion sizes, from the internal carotid artery to M2. By focusing on expediting and improving treatment effectiveness, Imperative Care aims to offer patients a greater chance for optimal recovery.

Carson Group Holdings, LLC, based in Omaha, Nebraska, provides a range of services to financial advisors and investors across the United States. The company operates through several subsidiaries, including Carson Wealth and Carson Group Coaching, offering coaching, partnership, and marketing support to financial advisors. It also delivers financial advice directly to investors, facilitating access to resources like a client-focused blog, marketing plans, and an integrated platform for operational and technological support. Carson Group specializes in lead generation marketing services and offers tailored consulting solutions in areas such as portfolio management, financial planning, risk management, and tax planning. Founded in 1983, Carson Group continues to support growth-oriented advisors and independent firms through its comprehensive services and resources.

Moveworks is a cloud-based AI platform purpose-built for large enterprises that solves one, big, frustrating problem: Resolving employees'​ IT support issues. Instead of tracking issues, we use advanced AI to solve them, instantly and automatically—with no human intervention. We count many of the world’s most recognizable brands as our customers. From hyper-growth startups to the Fortune 500, these companies rely on Moveworks to keep their employees productive and their businesses running smoothly. Moveworks is backed by Bain Capital Ventures and Lightspeed Venture Partners and is headquartered in Mountain View, California.

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

ConvenientMD Urgent Care offers convenient access to high-quality medical care, at the most affordable rates around. Patients can just walk in, without making an appointment, from 8 am to 8 pm, seven days a week. Patients are typically in and out in under 1 hour and there is always a full medical team on site. The center has friendly staff who provide world-class customer service with state-of-the-art medical equipment, including digital x-ray, lab, EKG, and IV equipment. ConvenientMD’s expert medical team is ready and equipped to treat a broad range of injuries and illness. ConvenientMD has NH locations in Bedford, Concord, Dover, Exeter, Keene, Merrimack, Nashua, Portsmouth, and Windham. Maine locations include Westbrook and Portland, with additional locations opening throughout New England.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

GreenLight Fund

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Hand in Hand Soap, founded in 2011 by Bill Glaab and Courtney Apple, is a personal care brand based in Wynnewood, Pennsylvania. The company offers a range of products, including bar soap, liquid hand soap, hand sanitizer, body wash, sugar scrubs, and lotions. Committed to social responsibility, Hand in Hand operates a Give Back program that donates a bar of soap and provides clean water to a child in need for every product sold. Over the past decade, the company has donated more than 13 million bars of soap and facilitated access to clean water for thousands. Additionally, Hand in Hand prioritizes sustainability by ensuring all its products are palm oil free, while raising awareness about the environmental and human rights issues associated with palm oil production.

Harry's, Inc. is a company that specializes in the manufacture and sale of shaving products. Founded in 2012 and headquartered in New York, the company designs and produces its own line of razors, replacement blades, shaving creams, grooming kits, and face care products. Harry's operates primarily through an online platform, offering its products individually or through a subscription model, catering to men's grooming needs. By focusing on quality and convenience, Harry's aims to simplify the shaving experience for consumers.

Newlink primarily operates as a digital energy service provider. It promotes energy change, the energy Internet of Things EIoT, and an energy new retail platform. It is a dual-material unicorn at home and abroad, one of the world's top 500 new energy companies, with more than 3,000 employees. Covering oil, electricity, hydrogen, and gas multiple energy categories, opening up the upstream and downstream of the energy industry chain, and digitally reconstructing the energy ecology.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Parksons Packaging Ltd. manufactures and supplies packaging products for fast moving consumer goods, food and beverages, pharmaceutical, electronic, retail, apparels, and other white good industries in India and internationally. It offers folding cartons and litho-laminated cartons. The company was founded in 1996 and is based in Mumbai, India.

Multi-Specialty HealthCare operates more than 30 patient care centers throughout the Baltimore-Washington metropolitan area and the Delmarva Peninsula. It employs a patient-centric, integrated model focused on delivering high-quality care to individuals injured in automobile and workplace accidents, regardless of their health insurance status. The company has a team of general practice and urgent care physicians, chiropractors, orthopedists, and other medical specialists who provide a full spectrum of treatment including physical rehabilitation, medical care, and other ancillary services.

TeachTown, Inc., an education company, develops computer aided instruction and new media products. It offers autism software and video modeling-based programs. The company provides TeachTown Basics, a computer-assisted instructional program that allows engaging on computer lessons along with motivational off computer activities for students. The company’s automatic data tracking and reporting system allows teachers to allot time for individual attention with their students, as well as enables them to address early learning standards and individualized education plan goals. It serves schools, families, and clinicians serving students with autism and other special needs. The company was founded in 2003 and is based in Los Angeles, Washington.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.

Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

AavantiBio, Inc. engages in developing gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. It focuses on Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company was incorporated in 2019 and is based in Gainesville, Florida.

Virgin Australia Holdings Limited engages in the operation of domestic and international passenger and cargo airline business in Australia. The company operates through Virgin Australia Domestic, Virgin Australia International, Velocity, and Tigerair Australia segments. Its aircraft flies to domestic destinations, including regional network, charter, and cargo operations; and international destinations comprising Trans-Pacific, Trans-Tasman, Pacific Island, and South East Asian flying, as well as international cargo operations. The company’s fleet primarily includes Boeing B737 and B777, Airbus A320 and A330, ATR, Embraer E190, and Fokker F100 aircraft. It also operates a frequent flyer program. The company serves corporate, government, leisure, low cost, regional, charter travelers, and air freight customers. It has strategic alliances with Air New Zealand Limited, Delta Air Lines Inc., Etihad Airways P.J.S.C., Singapore Airlines Limited, and HNA Aviation Group. The company was formerly known as Virgin Blue Holdings Limited and changed its name to Virgin Australia Holdings Limited in 2011. Virgin Australia Holdings Limited was founded in 2000 and is based in Bowen Hills, Australia.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Broadstep Behavioral Health provides a continuum of physical, emotional, and mental support for children and adults with intellectual and development disabilities (I/DD), mental illness, and co-occurring disorders. Broadstep has grown to now serve more than 1,300 individuals in 86 facilities across Wisconsin, North Carolina, New Jersey, Illinois and South Carolina. With outcomes rooted in discovering and championing personal definitions of progress, our individuals, families, caregivers, and neighbors are building more and more communities people can call home.

PresenceLearning, Inc. offers online special education services, including speech therapy, occupational therapy, behavioral interventions, and mental health support, to K-12 students and school districts across the United States and Canada. Utilizing a web-based videoconferencing platform, the company connects schools and parents with a network of licensed speech-language pathologists and other specialists through a variety of online tools and evidence-based therapeutic activities. Founded in 2009 and headquartered in San Francisco, California, PresenceLearning has established itself as a leader in delivering clinical services via the internet, successfully providing over 2.5 million teletherapy sessions since its inception. The company, formerly known as Presence Telecare, Inc., rebranded to its current name in August 2011.

RentoMojo is an online furniture rental platform that was incorporated in November 2014.It currently operates in Bangalore, Pune, Mumbai, Hyderabad, Chennai, Delhi, Gurgaon and Noida. RentoMojo was founded by Geetansh Bamania, an ex-IITM, in November 2014 in India. Like many other young working professionals, he was living in rented apartments, working long hours and found it inconvenient to equip the house with furniture when he moved. RentoMojo was developed to provide an alternative to buying and selling furniture in rental properties.

Showa Aircraft Industry Co., Ltd. is a manufacturer based in Akishima, Japan, specializing in transportation equipment both domestically and internationally. The company produces general purpose containers and transportation support vehicles, along with honeycomb cores and panels for aircraft and industrial applications, including satellites and cargo aircraft galleys. In addition to its core manufacturing activities, Showa Aircraft operates sports facilities for golf and tennis, manages hotels and shopping centers, and leases warehouse and commercial spaces. Established in 1937, the company has a diverse portfolio that extends beyond transportation equipment to include lifestyle support equipment. As of March 2020, Showa Aircraft Industry was taken private.

ST Unitas Co. Ltd. is an EduTech company that creates learning contents and programs to assist preparation for university entrance exams and job searching, as well as achieve language goals. It works with non-profit organizations, social enterprises, governments, global organizations, and other companies. The company was formerly known as ST & Company and changed its name to ST Unitas Co. Ltd. in May 2016. ST Unitas Co. Ltd. was founded in 2010 and is based in Seoul, South Korea with branches in Seoul, Busan, Incheon, Gyeonggi-do, Chungcheongnam-do, Gangwon-do, Ulsan, and Gyeongsangbuk-do, Korea.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.

A complete offer of business integration, application and infrastructure outsourcing, innovative solutions and strategic consultancy. The parent company Engineering Ingegneria Informatica has been listed on the Milan stock market since December 2000 and the ordinary shares are part of the FTSE Italia STAR index, which includes stock with the highest industrial and equity requisites. Designing and creating innovative architecture that guide and support all the organizations' business and service models in all markets. Promoting innovation in organizations, processes and services with the passion and enthusiasm of an Italian company.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Savara Inc. is a biopharmaceutical company based in Austin, Texas, specializing in rare respiratory diseases. Its primary product candidate, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Additionally, Molgradex is being evaluated in Phase IIa trials for nontuberculous mycobacterial (NTM) lung infections and cystic fibrosis patients with chronic NTM infections. Savara is also developing AeroVanc, an inhaled vancomycin, which is in Phase III trials for treating methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The company aims to expand its pipeline through strategic partnerships and product acquisitions, including a recent acquisition of a combination antibiotic that targets drug-resistant pathogens. Savara's management team has extensive experience in orphan drug development and is focused on addressing unmet medical needs in the field of pulmonary medicine.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices aimed at monitoring and managing acute medical conditions, particularly in the cardiac care sector. Founded in 2014 and headquartered in Kirkland, Washington, the company offers innovative solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its primary products is a wearable cardioverter defibrillator designed to prevent sudden cardiac death and support cardiac recovery in at-risk patients. These devices integrate advanced technologies to deliver vital information, thereby enhancing the ability of patients and their healthcare teams to monitor and manage health effectively.

Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Imperative Care, Inc. is a medical technology company dedicated to enhancing acute stroke treatment. Founded in 2015 and based in Campbell, California, the company develops innovative solutions aimed at addressing critical needs in stroke care. Its primary offerings include the Large Distal Platform, a large diameter catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic strokes. Additionally, the ZOOM Aspiration System works in conjunction with the Large Distal Platform, providing a comprehensive solution for clot removal across various occlusion sizes, from the internal carotid artery to M2. By focusing on expediting and improving treatment effectiveness, Imperative Care aims to offer patients a greater chance for optimal recovery.

Reonomy is a commercial real estate data and analytics platform that integrates extensive property information to assist professionals in sourcing deals and making informed decisions. By utilizing big data, partnerships, and machine learning, Reonomy connects various fragmented aspects of the commercial real estate market, offering users access to comprehensive property intelligence. The platform provides valuable insights by combining data on properties, companies, and individuals, enabling lenders, brokers, and investors to identify opportunities and engage with real estate owners effectively. Through its innovative approach, Reonomy empowers users to navigate the complexities of the real estate landscape with greater clarity and confidence.

Reonomy is a commercial real estate data and analytics platform that integrates extensive property information to assist professionals in sourcing deals and making informed decisions. By utilizing big data, partnerships, and machine learning, Reonomy connects various fragmented aspects of the commercial real estate market, offering users access to comprehensive property intelligence. The platform provides valuable insights by combining data on properties, companies, and individuals, enabling lenders, brokers, and investors to identify opportunities and engage with real estate owners effectively. Through its innovative approach, Reonomy empowers users to navigate the complexities of the real estate landscape with greater clarity and confidence.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

IQVIA, Inc. is a global provider of information and technology services tailored for the healthcare industry. The company specializes in collecting and organizing comprehensive healthcare data, including sales, prescriptions, medical claims, and electronic medical records. IQVIA offers a range of solutions, such as IMS One, a cloud application for business analytics that allows clients to analyze healthcare data related to diseases, treatments, costs, and outcomes. Its services also include commercial applications for sales operations, real-world evidence solutions for evaluating treatment value, and clinical solutions to support the design and execution of clinical trials. The company serves a diverse clientele, including pharmaceutical manufacturers, medical device companies, providers, payers, government agencies, and researchers. Founded in 2010 and based in Danbury, Connecticut, IQVIA, Inc. operates as a subsidiary of IQVIA Holdings Inc.

Opsani uses the capabilities of AI to optimize applications in the cloud. It is a provider of Machine Learning driven automation to enable autonomous operations for DevOps teams. Founded by a team of seasoned entrepreneurs, who pioneered some of the major innovations that power current IT, Opsani applies AI to automatically improve operations of applications and cloud infrastructure to achieve better performance. Opsani was founded as Datagrid Systems by Ross Schibler, Bert Armijo, and Peter Nickolov in November 2014. The company name was changed to Opsani in July 2017.

Attivo Networks provides required visibility and actionable, substantiated alerts to detect, isolate, and defend against cyber attacks. Attivo Networks, the leader in deception technology, provides accurate in-network threat detection, analysis, and accelerated response to advanced, credential, insider, and ransomware attacks. The Attivo Deception and Response Platform provide continuous visibility and efficient threat management for user networks, data centers, cloud, branch, IoT, ICS-SCADA, and POS environments. Camouflage dynamic deception sets high-interaction traps to misdirect and lure attackers into revealing themselves. The solution’s advanced attack analysis and lateral movement tracking automate investigation, deliver evidence-based alerts, and in-depth forensic reports. Incident response is simplified with ThreatOps™ playbooks and 3rd party integrations for automated attack blocking, quarantine, and threat hunting.

Cameo is a marketplace that allows fans to book personalized video shoutouts from a wide array of talent, including celebrities and influencers. The platform aims to provide authentic and personalized fan experiences, offering users the opportunity to connect with their favorite personalities through custom video messages. With partnerships spanning various verticals, Cameo has established itself as a prominent player in the entertainment industry. The company is based in Chicago and is part of the city's vibrant technology and startup community.

Rodeo Dental & Orthodontics is a medical practice based in Fort Worth, Texas, specializing in a range of dental services. Founded in 2009, the company provides general dentistry, orthodontics, endodontics, oral surgery, and pediatric dental care. With multiple locations across the United States, Rodeo Dental & Orthodontics aims to deliver comprehensive dental solutions to meet the needs of patients of all ages.

Qinhuai Data was established in 2004. The company focuses on industrial ecological planning, investment, construction, testing and operation of cloud computing infrastructure. The controlling shareholder, NetScience Technology Co., Ltd., is the leading joint-stock listed company in the field of Internet computing in China. It mainly provides customers with global content distribution and acceleration, server hosting and leasing, and network optimization for bandwidth resources. supplier. In August 2015, we jointly established Beijing Qinhuai Data Co., Ltd. with NetScience Technology, invested and operated its own IDC Internet data center in Beijing, Shanghai, Guangzhou and Shenzhen, and leased and operated more than 170 operators' operating rooms worldwide in the data center. Provide resources and services to partners in the entire ecological industry chain for resource development, project operation and maintenance of construction operations, IT server hardware custom operation and maintenance, broadband access value-added services, and long-distance transmission link solutions.

Tealium, Inc. provides enterprise tag management solutions to clients worldwide. The company offers Tealium iQ, a tag management solution that allows business users to manage their tags across multiple digital touchpoints, such as Web, mobile, and video. Its Tealium iQ solution allows digital marketers to manage their online solutions; and deploy and manage third-party vendor tags, as well as correlate the data those tags generate into an actionable source. It also provides supported tags; Tealium DataCloud, a digital data platform; Mobile Tagging that helps digital marketers to improve mobile marketing; and AudienceStream, a real-time audience discovery platform for marketers. In addition, it offers Tealium DataAccess that enables customers to unify various omnichannel insights from anywhere across the organization to allow for real-time informed engagement and action; and Tealium Predict, a built-in machine learning technology for Tealium AudienceStream. The company serves brands in various industry categories, including e-commerce, online media, travel, and more. Tealium, Inc. was founded in 2008 and is based in San Diego, California.

RentoMojo is an online furniture rental platform that was incorporated in November 2014.It currently operates in Bangalore, Pune, Mumbai, Hyderabad, Chennai, Delhi, Gurgaon and Noida. RentoMojo was founded by Geetansh Bamania, an ex-IITM, in November 2014 in India. Like many other young working professionals, he was living in rented apartments, working long hours and found it inconvenient to equip the house with furniture when he moved. RentoMojo was developed to provide an alternative to buying and selling furniture in rental properties.

SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others. The company was founded in 2017 and headquartered in Connecticut, United States.

Founded with the goal of connecting companies with talented, qualified IT professionals living in cities across the United States, our team members are the foundation of our company. With an average of 10 years of development experience, each team member brings something unique to the job. Our colleagues are able to live in high quality of life, low cost of living areas while working on a variety of interesting, collaborative and challenging projects. Over the last decade, we’ve bridged the gap between businesses and professionals living and working in communities across the country.

Qinhuai Data was established in 2004. The company focuses on industrial ecological planning, investment, construction, testing and operation of cloud computing infrastructure. The controlling shareholder, NetScience Technology Co., Ltd., is the leading joint-stock listed company in the field of Internet computing in China. It mainly provides customers with global content distribution and acceleration, server hosting and leasing, and network optimization for bandwidth resources. supplier. In August 2015, we jointly established Beijing Qinhuai Data Co., Ltd. with NetScience Technology, invested and operated its own IDC Internet data center in Beijing, Shanghai, Guangzhou and Shenzhen, and leased and operated more than 170 operators' operating rooms worldwide in the data center. Provide resources and services to partners in the entire ecological industry chain for resource development, project operation and maintenance of construction operations, IT server hardware custom operation and maintenance, broadband access value-added services, and long-distance transmission link solutions.

HealthDrive was founded in 1989 by medical professionals who saw the need for a higher level of on-site medical and dental services in long-term care facilities. Their founders began assembling specialty doctors, skilled providers and practitioners who were rated to be the best in their field. Since then, HealthDrive has grown to employ 120 medical and dental providers in over 1,000 facilities, serving more than 135,000 senior living residents around the nation. They understand the critical importance of good health and how it leads to a better quality of life. Their highly skilled on-site medical service providers not only deliver proactive healthcare to seniors in long-term care facilities, but deliver those services with the utmost care and empathy. HealthDrive provides long-term care residents with dental, optometry, podiatry and audiology services where they reside, bringing services to senior living facilities who partner with us. Learn more about what makes us a leading provider:

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

Centric Health provides a new and innovative approach to the provision of quality primary healthcare in Ireland, the UK and Australia. Their mission is to 'strive to keep people healthy in their own community' where often they can be equally or more effectively treated than through the hospital system. They provide a wide spectrum of accessible and innovative medical services, many of which would traditionally only have been available through the hospital system. These services are proactive and responsive to local needs and include providing 10 community GP in Dublin, urgent care, Occupational Health Care, diagnostic services and the treatment of chronic conditions. Their success has been putting patients and their needs at the centre of everything that they do.

TidalScale, Inc. develops software for in-memory applications that binds multiple commodity hardware servers into a unified software virtual machine. It offers TidalScale software-defined servers that represent the next wave of compute. The company’s technology also helps users to configure virtual servers of various sizes, and achieve in-memory performance for the big data workloads. Its solutions include Oracle database, SAP HANA, and data analytics. TidalScale, Inc. was incorporated in 2012 and is based in Campbell, California with additional offices in Seoul, South Korea; Tokyo, Japan.

LivHOME offers a variety of professional home care services which include personal care, respite care, companion care, dementia care, and more. Their caregivers are available on an hourly or 24-hour basis with flexible hours and no long-term contracts. LivHOME offers the most comprehensive home care services for the elderly, providing a combination of caregiving, care management, and care technology that have shown to improve outcomes at home while contributing to your loved one’s well-being.

Rocket Software, Inc. develops and supports enterprise software solutions that cater to a diverse range of industries, including automotive, healthcare, finance, and technology. Founded in 1990 and headquartered in Waltham, Massachusetts, the company provides products in various domains such as application lifecycle management, data management, business intelligence, and modernization. Rocket Software also offers training, consulting, and professional services to enhance its software solutions. The company has a global presence with offices in North America, Europe, and Asia, and it serves clients that include hardware and software vendors, OEMs, and various sectors seeking to improve their operational efficiencies and data management capabilities.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Venminder, Inc. is a provider of a cloud-based software-as-a-service platform focused on third-party risk management. The platform facilitates the assessment, monitoring, and management of vendor-related risks through various modules, including vendor oversight, contract management, risk assessments, and examination preparation. Venminder's comprehensive services encompass document collection, financial statement analysis, cybersecurity reviews, and vendor monitoring, enabling organizations to gain insights into their vendors' compliance and financial health. The company serves a diverse range of industries, including financial services, healthcare, insurance, education, and retail. Founded in 2001 and based in Elizabethtown, Kentucky, with an additional office in Chicago, Venminder was formerly known as Digital Comply, Inc. and rebranded in April 2016. The platform also supports a community called Third Party ThinkTank, aimed at professionals in third-party risk management.

Centrient Pharmaceuticals develops, produces, and sells generic intermediates, active pharmaceutical ingredients (API), and drug products (DP). The products include penicillin G, beta-lactam intermediates, semi-synthetic penicillins, isoxazoles, cephalosporins, statins, and anti-fungals. Centrient Pharmaceuticals was formerly known as DSM Sinochem Pharmaceuticals Pte. Ltd. and changed its name to Centrient Pharmaceuticals in December 2018. The company was incorporated in 1869 and is based in Singapore.

Italmatch Chemicals majors in the production of phosphorus derivatives, giving it a unique strength and leading position in the international market. Although a relatively small company, compared to its main competitors, Italmatch Chemicals has earned the respect and trust, over a period of years, of such Multinationals leaders in their sectors, with particular regard to lubricant oil additives (L.O.A.), plastic & polymers flame retardant additives (F.R.) and other various industrial applications. The wide sector already encompassed by Italmatch Chemicals is destined to expand even larger thanks to its historical ambition of growth. The ability to combine the reliability of tradition with the opportunities offered by modern technology, implemented by an expert and dynamic management, results in Italmatch Chemical’s unparalleled creativity, competence and Customers satisfaction. By focusing on today’s dynamic world of specialty chemicals and its expanding horizons, Italmatch Chemicals offers advanced and effective solutions based largely, but not exclusively, on phosphorus derivatives. Careful environmental concern stands to witness the Company long term commitment to the market, as the technologically advanced systems adopted in its Spoleto plant stand to prove, with particular respect to the optimisation of environmental impact and increased safety. For these reasons the Company has recently obtained the ISO 14001:2004 Environmental Certification, and is operating according to both an Environmental Management System as well as a Safety Management System, both subject to periodical revisions and audits.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Penn Foster College, Penn Foster Career School, and Penn Foster High School are part of Penn Foster, Inc., a global leader in online education. For more than 118 years, Penn Foster has been providing accredited career-focused degree and vocational programs in the fields of allied health, business, technology, education, and select trades. Nationally and regionally accredited Penn Foster High School (www.PennFosterHighSchool.com) and Penn Foster Career School (www.pennfoster.edu) are headquartered in Scranton, PA, with regional offices in Montreal, Canada. Penn Foster College is headquartered in Scottsdale, Arizona.

Fedrigoni S.p.A. is an Italian manufacturer specializing in paper products, self-adhesive labels, and related items. The company offers a diverse range of products, including adhesive papers and films for industrial labeling, specialty media for office use, and coated papers for publishing and packaging. Its product line also encompasses stationery, art supplies, and security paper for banknotes. With a focus on customization, Fedrigoni collaborates closely with clients to deliver tailor-made solutions, supported by a robust inventory of over 3,000 items. Established in 1888 and headquartered in Verona, Italy, the company operates through a network of branches across Italy, Europe, and Asia, ensuring efficient distribution of its products. As a family-run business, Fedrigoni has navigated economic challenges while expanding its global reach in various sectors, including beverages, fashion, and pharmaceuticals.